Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Branchi, Adriana; Rovellini, A.; Sommariva, D.; Gugliandolo, Angelo G; Fasoli, A

doi:10.1055/s-0038-1649476

Cited by 121 publications

(56 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Genetic Polymorphismssupporting

confidence: 76%

“…27,29,30 Also, the linkage disequilibrium between the polymorphism on the ␤-and ␣-fibrinogen genes in our CAD patients is comparable to that described for healthy white populations. 27,29 The ECTIM study also reported comparable allele frequencies of the ␤-fibrinogen gene polymorphisms in myocardial infarction patients and healthy control subjects. 23,24 As in other studies, we found in our patient group that individuals homozygous for the Ϫ455A allele showed a higher plasma fibrinogen level than individuals homozygous for the Ϫ455G allele.…”

Section: Genetic Polymorphismssupporting

confidence: 76%

See 1 more Smart Citation

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

Maat

Kastelein

Jukema

et al. 1998

ATVB

145

View full text Add to dashboard Cite

Abstract-Increased plasma fibrinogen levels have been identified as a risk indicator for myocardial infarction, stroke, and thrombosis. Both environmental and genetic factors make an important contribution to plasma fibrinogen levels in humans. In the present study we evaluated, in patients with serum cholesterol levels between 4 and 8 mmol/L, the relation of plasma levels and polymorphisms of fibrinogen with coronary artery disease (CAD), cross-sectionally at baseline and after a 2-year follow-up period in which they received either a placebo or pravastatin. Higher plasma fibrinogen levels (3.9 g/L) were observed at baseline in patients with the Ϫ455AA genotype than in patients with the Ϫ455GA (3.2 g/L) and Ϫ455GG (3.1 g/L) genotypes of the Ϫ455G/A fibrinogen ␤ gene polymorphism (PϽ.05). Plasma levels of fibrinogen were not related to the baseline angiographic variables (mean segment diameter [MSD] and minimum obstruction diameter [MOD]), nor to the quantitative changes in these angiographic variables. However, in the placebo group, patients with the Ϫ455AA genotype had more progression of CAD, expressed by a significantly greater decrease of the MSD and MOD, after the 2-year follow-up period than patients with the other genotypes. The Ϫ455G/A polymorphism was related to the progression of CAD, and pravastatin therapy seemed to offset this deleterious effect. We hypothesized that the Ϫ455A allele may promote a stronger acute-phase response in fibrinogen and that the resulting higher fibrinogen levels may form the pathogenetic basis for the stronger progression of coronary atherosclerosis. Experiments to verify this hypothesis are being proposed and advocated, in view of the possibility of identifying a genetic marker that can recognize a subgroup of patients with an increased risk who may benefit from early treatment with lipid-lowering or anticoagulant drugs.(Arterioscler Thromb Vasc Biol. 1998;18:265-271.)

show abstract

Section: Genetic Polymorphismssupporting

confidence: 76%

Section: Genetic Polymorphismssupporting

confidence: 76%

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

Maat

Kastelein

Jukema

et al. 1998

ATVB

145

View full text Add to dashboard Cite

show abstract

“…The Lp(a) concentration responds well to estrogen (28 ) and nicotinic acid (29, 30 ) but not to statins, which effectively lower plasma cholesterol concentrations, with some studies showing an increase (31,32 ) and others showing no effect on Lp(a) concentration (19 -21 ). Xuezhikang contains a family of monacolin-related substances, one of which is a naturally occurring lovastatin (22,23 ).…”

Section: Discussionmentioning

confidence: 99%

Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease

Liu¹,

Zhao²,

Cheng³

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

Background: Increased serum lipoprotein(a) [Lp(a)] andhigh-sensitivity C-reactive protein (hsCRP) concentrations are independent risk factors for coronary heart disease (CHD). Xuezhikang, an extract of cholestin, effectively lowers fasting cholesterol and triglyceride concentrations. We studied whether xuezhikang lowered Lp(a) and hsCRP concentrations. Methods: We randomly divided 60 CHD patients into two groups to receive xuezhikang (1200 mg daily) or placebo for 6 weeks. The fasting hsCRP concentration and the postprandial changes of serum lipid concentrations at 2, 4, and 6 h after a high-fat meal (800 calories; 50 g of fat) were measured before and after the 6-week protocol. Results: The two groups had similar baseline fasting lipid and hsCRP concentrations. The postprandial triglyceride and Lp(a) concentrations were significantly increased (P <0.05). After 6 weeks, the fasting and postprandial lipid concentrations decreased significantly in the xuezhikang group, accompanied by a significant reduction in fasting hsCRP concentration (P <0.001). The placebo group had no significant change in lipid concentrations, whereas the fasting serum hsCRP concentration was reduced significantly (P <0.05). The reduction in hsCRP was closely related to the changes in fasting Lp(a) concentration (r ‫؍‬ 0.402; P <0.05) and triglyceride area under the curve (r ‫؍‬ 0.441; P <0.001). Conclusions: Xuezhikang effectively decreased fasting Lp(a) and postprandial triglyceride concentrations, which were associated with reductions of fasting hsCRP concentrations in CHD patients.

show abstract

“…In this context, it should be noted that ®brates exert a favourable in¯uence on nonlipid CHD risk factors related to hemostatic imbalance such as elevated plasminogen activator inhibitor-1 and ®brinogen. 3,11,12 Both risk factors are highly prevalent in abdominal obesity, and are associated with the degree of hyperinsulinism. 13,14 Hyperinsulinism and insulin resistance are often related to low HDL and high triglyceride levels, and to disturbed haemocoagulation factors in obesity.…”

Section: Discussionmentioning

confidence: 99%

Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates

Muls

Gaal²,

Autier

et al. 1997

Int J Obes

View full text Add to dashboard Cite

OBJECTIVE: To assess the effects of BMI at baseline and on-treatment weight change on the lipid-lowering ef®cacy of diet plus ®bric acid derivatives (®brates) in hypercholesterolemic adults. SUBJECTS: 6003 participants in a Belgian General Practitioners Trial, an open-label, prospective study conducted in a primary care setting. MEASURES: Effect of initial BMI, on-treatment weight change, or lipid values at baseline on percentage changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Multiple linear regression models, including initial BMI, on-treatment weight change, age, gender, and baseline lipid values, were ®tted to control the in¯uences exerted by these variables on each other. RESULTS: Reductions in LDL-C after diet plus ®brate treatment for 12 weeks were inversely related to initial BMI and to TG levels at baseline, and were positively associated with baseline LDL-C concentrations and with on-treatment weight change (P`0.001 for all analyses). Decreases in TG related negatively with initial BMI (P 0.012), and positively with weight loss (P 0.011) and TG at baseline (P`0.001). Increases in HDL-C were negatively associated with initial BMI (P 0.012) and with baseline TG (P`0.001). CONCLUSIONS: The LDL-C lowering ef®cacy of ®brates is inversely related to initial BMI, and is positively associated with on-treatment weight loss.

show abstract

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Cited by 121 publications

References 11 publications

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

−455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men

Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease

Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates

Contact Info

Product

Resources

About